Drugs that contain Leuprolide Acetate
1. Eligard Kit patents expiration
ELIGARD KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486455 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US9283282 | TOLMAR | Sustained release polymer |
Oct, 2018
(5 years ago) | |
| US9254307 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US9539333 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US9914802 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US8470359 | TOLMAR | Sustained release polymer |
Oct, 2023
(6 months ago) | |
| US11771841 | TOLMAR | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(17 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395293 | TOLMAR | Biodegradable implant precursor |
Sep, 2013
(10 years ago) | |
| US5599552 | TOLMAR | Biodegradable polymer composition |
Feb, 2014
(10 years ago) | |
| US6565874 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US6773714 | TOLMAR | Polymeric delivery formulations of leuprolide with improved efficacy |
Oct, 2018
(5 years ago) | |
| US6626870 | TOLMAR | Stoppering method to maintain sterility |
Mar, 2020
(4 years ago) | |
| US8840916 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
Market Authorisation Date: 13 February, 2003
Treatment: Method of treating cancer; Palliative treatment of prostate cancer
Dosage: POWDER;SUBCUTANEOUS
More Information on Dosage
ELIGARD KIT family patents
2. Fensolvi Kit patents expiration
FENSOLVI KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9539333 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US9914802 | TOLMAR | Sustained release polymer |
Nov, 2020
(3 years ago) | |
| US8470359 | TOLMAR | Sustained release polymer |
Oct, 2023
(6 months ago) | |
| US11771841 | TOLMAR | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-829) | May 01, 2023 |
Market Authorisation Date: 01 May, 2020
Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty
Dosage: POWDER;SUBCUTANEOUS
More Information on Dosage
FENSOLVI KIT family patents
3. Leuprolide Acetate For Depot Suspension patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789064 | INVAGEN PHARMS | Method for delivering a peptide to a subject at a modulated rate via microcapsules of lactic-co-glycolic copolymer containing said peptide |
Dec, 2020
(3 years ago) | |
Market Authorisation Date: 28 August, 2018
Treatment: NA
Dosage: FOR SUSPENSION;INTRAMUSCULAR
More Information on Dosage
LEUPROLIDE ACETATE FOR DEPOT SUSPENSION family patents
4. Lupron Depot patents expiration
LUPRON DEPOT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5480656 | ABBVIE ENDOCRINE INC | Prolonged release microcapsules |
Jan, 2013
(11 years ago) | |
| US5643607 | ABBVIE ENDOCRINE INC | Prolonged release microcapsules |
Jan, 2013
(11 years ago) | |
| US5716640 | ABBVIE ENDOCRINE INC | Method of producing sustained-release microcapsules |
Sep, 2013
(10 years ago) | |
| US5575987 | ABBVIE ENDOCRINE INC | Method of producing sustained-release microcapsules |
Sep, 2013
(10 years ago) | |
| US5631020 | ABBVIE ENDOCRINE INC | Method for producing microcapsule |
May, 2014
(9 years ago) | |
| US5631021 | ABBVIE ENDOCRINE INC | Method for producing microcapsule |
May, 2014
(9 years ago) | |
| US6036976 | ABBVIE ENDOCRINE INC | Sustained release microspheres and preparation thereof |
Dec, 2016
(7 years ago) | |
| US7429559 | ABBVIE ENDOCRINE INC | Controlled release composition and method of producing the same |
Jan, 2019
(5 years ago) | |
| US8815801 | ABBVIE ENDOCRINE INC | Controlled release composition and method of producing the same |
Jun, 2022
(1 year, 9 months ago) | |
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(6 years from now) | |
Market Authorisation Date: 07 March, 1997
Treatment: Palliative treatment of prostate cancer
Dosage: INJECTABLE;INJECTION
How can I launch a generic of LUPRON DEPOT before it's drug patent expiration?
More Information on Dosage
LUPRON DEPOT family patents
5. Lupron Depot-ped Kit patents expiration
LUPRON DEPOT-PED KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5480656 | ABBVIE ENDOCRINE INC | Prolonged release microcapsules |
Jan, 2013
(11 years ago) | |
| US5643607 | ABBVIE ENDOCRINE INC | Prolonged release microcapsules |
Jan, 2013
(11 years ago) | |
| US5575987 | ABBVIE ENDOCRINE INC | Method of producing sustained-release microcapsules |
Sep, 2013
(10 years ago) | |
| US5716640 | ABBVIE ENDOCRINE INC | Method of producing sustained-release microcapsules |
Sep, 2013
(10 years ago) | |
| US5631020 | ABBVIE ENDOCRINE INC | Method for producing microcapsule |
May, 2014
(9 years ago) | |
| US6036976 | ABBVIE ENDOCRINE INC | Sustained release microspheres and preparation thereof |
Dec, 2016
(7 years ago) | |
| US9617303 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Mar, 2028
(3 years from now) | |
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Apr 14, 2026 |
| M(M-107) | Oct 08, 2014 |
| New Product(NP) | Aug 15, 2014 |
Market Authorisation Date: 16 April, 1993
Treatment: Treatment of pediatric patients with central precocious puberty
Dosage: POWDER;INTRAMUSCULAR
More Information on Dosage
LUPRON DEPOT-PED KIT family patents
6. Viadur patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395292 | ORTHO MCNEIL JANSSEN | Sustained delivery of an active agent using an implantable system |
Jan, 2017
(7 years ago) | |
| US5985305 | ORTHO MCNEIL JANSSEN | Sustained delivery of an active agent using an implantable system |
Jan, 2017
(7 years ago) | |
| US6156331 | ORTHO MCNEIL JANSSEN | Sustained delivery of an active agent using an implantable system |
Jan, 2017
(7 years ago) | |
| US5728396 | ORTHO MCNEIL JANSSEN | Sustained delivery of leuprolide using an implantable system |
Jan, 2017
(7 years ago) | |
| US6132420 | ORTHO MCNEIL JANSSEN | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
Jan, 2017
(7 years ago) | |
| US6235712 | ORTHO MCNEIL JANSSEN | Non-aqueous polar aprotic peptide formulations |
Jun, 2017
(6 years ago) | |
| US5932547 | ORTHO MCNEIL JANSSEN | Non-aqueous polar aprotic peptide formulations |
Jun, 2017
(6 years ago) | |
| US6124261 | ORTHO MCNEIL JANSSEN | Non-aqueous polar aprotic peptide formulations |
Jun, 2017
(6 years ago) | |
| US6113938 | ORTHO MCNEIL JANSSEN | Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents |
Jul, 2018
(5 years ago) | |
| US6375978 | ORTHO MCNEIL JANSSEN | Rate controlling membranes for controlled drug delivery devices |
Dec, 2018
(5 years ago) | |
Market Authorisation Date: 03 March, 2000
Treatment: Method of treating a subject suffering from prostate cancer
Dosage: IMPLANT;IMPLANTATION
More Information on Dosage
VIADUR family patents